34 
While H.R. 11192 also provides for the imposition of penalties on 
laboratories with violations, HEW estimates that few, if any, penal- 
ties will be assessed. 
7. Estimate comparison : None. 
8. Previous CBO estimate : None. 
9. Estimate prepared by : John Nelson (225-7766) . 
10. Estimate approved by: James L. Blum, Assistant Director for 
Budget Analysis. 
PROGRAM OVERSIGHT 
The committee’s principal oversight activities with respect to this 
program have been conducted by the Subcommittee on Health and 
the Environment in connection with its consideration of the legisla- 
tive authorities for the program. Legislative hearings on the program 
were conducted in March of 1977 (Serial No. 95-18) , and the findings 
are discussed in the report as the proposed legislation is designed to 
respond to the subcommittee’s findings. The committee has not re- 
ceived oversight findings with respect to this program from its Sub- 
committee on Oversight and Investigations or from the Committee on 
Government Operations. Published hearings on the science policy im- 
plications of DNA recombinant molecule research were conducted by 
the Subcommittee on Science, Research and Technology of the Com- 
mittee on Science and Technology in 1977 which were useful to the 
committee in its deliberations. 
AGENCY REPORTS 
Agency reports were requested on H.R. 4759, a similar predeces- 
sor to H.R. 11192, from the Office of Management and Budget and 
the Department of Health, Education, and Welfare, but to date no 
reports have been received. 
[Appendix B — 164] 
